Development of and insights from systems pharmacology models of antibody‐drug conjugates

Simulating the Selection of Resistant Cells with Bystander Killing and Antibody Coadministration in Heterogeneous Human Epidermal Growth Factor Receptor 2–Positive Tumors

(2021) Bruna Menezes et al.   DRUG METABOLISM AND DISPOSITION

Antibody Coadministration as a Strategy to Overcome Binding-Site Barrier for ADCs: a Quantitative Investigation

(2020) Aman P. Singh et al.   AAPS Journal

An Agent-Based Systems Pharmacology Model of the Antibody-Drug Conjugate Kadcyla to Predict Efficacy of Different Dosing Regimens

(2020) Bruna Menezes et al.   AAPS Journal

Evaluation of Quantitative Relationship Between Target Expression and ADC Exposure Inside Cancer Cells

(2020) Sharad Sharma et al.   DRUG METABOLISM AND DISPOSITION

Evolution of the Systems PK-PD Model for Antibody-drug Conjugates (ADC) to Characterize Tumor Heterogeneity and In Vivo Bystander Effect

(2020) Aman P Singh et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

A Cell-Level Systems PK-PD Model to Characterize In Vivo Efficacy of ADCs

(2019) Aman Singh et al.   Pharmaceutics

A “Dual” Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC

(2019) Aman P. Singh et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index

(2019) Steven Coats et al.   CLINICAL CANCER RESEARCH

Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy

(2019) Sajad Yaghoubi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology

(2019) Kirill Peskov et al.   Frontiers in Immunology

Antibody-Drug Conjugates: A Comprehensive Review

(2019) Puregmaa Khongorzul et al.   MOLECULAR CANCER RESEARCH

Establishing in vitro–in vivo correlation for antibody drug conjugate efficacy: a PK/PD modeling approach

(2018) Dhaval K. Shah et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

The Spectrum of Mechanism-Oriented Models and Methods for Explanations of Biological Phenomena

(2018) C. Hunt et al.   Processes

Strategies and challenges for the next generation of antibody–drug conjugates

(2017) Alain Beck et al.   NATURE REVIEWS DRUG DISCOVERY

Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)

(2017) Ricarda M. Hoffmann et al.   OncoImmunology

Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1)

(2016) Aman P. Singh et al.   AAPS Journal

Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin

(2016) Alison M. Betts et al.   AAPS Journal

Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics

(2016) Siddharth Sukumaran et al.   AAPS Journal

Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design

(2016) Katie F. Maass et al.   AAPS Journal

Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy

(2016) Cornelius Cilliers et al.   AAPS Journal

Antibody-drug conjugates for non-oncological indications

(2016) Renhe Liu et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Quantitative characterization of in vitro bystander effect of antibody-drug conjugates

(2016) Aman P. Singh et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Antibody–drug conjugates for cancer therapy

(2016) Anish Thomas et al.   LANCET ONCOLOGY

Altering Antibody–Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability

(2016) Kevin J. Hamblett et al.   MOLECULAR PHARMACEUTICS

Antibody-drug conjugates as novel anti-cancer chemotherapeutics

(2015) C. Peters et al.   BIOSCIENCE REPORTS

Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development

(2015) Aman P. Singh et al.   PHARMACEUTICAL RESEARCH

Molecular mechanism matters: Benefits of mechanistic computational models for drug development

(2015) Lindsay E. Clegg et al.   PHARMACOLOGICAL RESEARCH

A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design

(2015) Christina Vasalou et al.   PLoS One

A Priori Prediction of Tumor Payload Concentrations: Preclinical Case Study with an Auristatin-Based Anti-5T4 Antibody-Drug Conjugate

(2014) Dhaval K. Shah et al.   AAPS Journal

A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer

(2014) Brendan Bender et al.   AAPS Journal

Modeling cancer-immune responses to therapy

(2014) L. G. dePillis et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

The level of HER2 expression is a predictor of antibody-HER2 trafficking behavior in cancer cells

(2014) Sripad Ram et al.   mAbs

Target-mediated drug disposition model and its approximations for antibody–drug conjugates

(2013) Leonid Gibiansky et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach

(2013) Nahor Haddish-Berhane et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Bioanalysis of antibody–drug conjugates: American Association of Pharmaceutical Scientists Antibody–Drug Conjugate Working Group position paper

(2013) Boris Gorovits et al.   Bioanalysis

Immuno-oncology: understanding the function and dysfunction of the immune system in cancer

(2012) O. J. Finn   ANNALS OF ONCOLOGY

Antibody-Drug Conjugates in Cancer Therapy

(2012) Eric L. Sievers et al.   Annual Review of Medicine

Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin

(2012) Dhaval K. Shah et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

A Systems Approach for Tumor Pharmacokinetics

(2011) Greg Michael Thurber et al.   PLoS One

Interactions Between the Immune System and Cancer: A Brief Review of Non-spatial Mathematical Models

(2010) Raluca Eftimie et al.   BULLETIN OF MATHEMATICAL BIOLOGY

Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies

(2009) Laurent Ducry et al.   BIOCONJUGATE CHEMISTRY